Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas

Table 1

Studies on high-dose therapy and autologous stem cell transplantation in PTCL as second-line therapy.

Retrospective data
Author	Year	𝑛	Age	Histologies (WHO)	IPI	High-dose regimen	Status at Tx	DFS/EFS/ PFS/RFS	OS	Followup (months)	Comment
Vose et al. [22]	1990	17	33	No data∗	No data	Diverse	CR 42%; PR 26%	28% (2 y)	35% (2 y)	28
Fanin et al. [23]	1999	64	25	ALCL 100%	aaIPI; 0/1   48%; 2/3   22%; Unknown 30%	Diverse	CR 47%	56% (5 y)	70% (5 y)	43	34/64 transplanted 2.line
Rodríguez et al. [24]	2001	29	43	No data∗	0/1   31%; 2   41%; 3   21%; 4/5   7%	Diverse	CR 38%; PR 48%	32% (3 y)	39% (3 y)	43
Blystad et al. [25]	2001	40	42	PTCLu 50%; ALCL 35%; Other 15%	aaIPI; 0/1   42%; 2/3   45%; Unknown 13%	Diverse	CR 70%; PR 30%	56% (3 y)	58% (3 y)	25	23/40 transplanted 2.line
Song et al. [26]	2002	36	46	PTCLu 56%; ALCL 25%; NK/T 11%; Other 8%	No data	Mel/Eto	CR 42%; PR 50%	37% (3 y)	48% (3 y)	42
Rodríguez et al. [27]	2003	115	41	PTCLu 63%; ALCL 22%; NK/T 15%	aaIP; 0/1   40%; 2/3   60%	Diverse	CR 56%; PR 38%	60% (5 y); 49% (5 y)∗∗	56% (5 y); 45% (5 y)∗∗	37	78/115 transplanted 2.line
Schetelig et al. [28]	2003	29	51	AITL 100%	aaIPI; 0/1   21%; 2/3   79%	Diverse	No data	37% (5 y); 39% (5 y)∗∗	60% (5 y); 44% (5 y)∗∗	60	15/29 transplanted 2.line
Zamkoff et al. [29]	2004	16	52	ALK^−ALCL 100%	aaIPI; 0/1   67%; 2/3   33%	Diverse	CR 60%; PR 40%	12 w (median)	72 w (median)	No data
Jantunen et al. [30]	2004	37	46	PTCLu 38%; ALCL 38%; EATL 14%; Other 11%	0/1   46%; 2   22%; 3   19%; 4/5   14%; Unknown 3%	BEAC/BEAM	CR/PR 87%	44% (5 y); 28% (5 y)∗∗	54% (5 y); 45% (5 y)∗∗	24	19/37 transplanted 2.line TRM 16%
Jagasia et al. [31]	2004	28	39	ALCL 57%; PTCLu 21%; AITL 11%; NK/T 11%	aaIPI; 0/1   29%; 2/3   50%; Unknown 21%	Cy/Eto/TBI or CBV	CR 39%; PR 46%	50% (3 y)	69% (3 y)	44	7/28 underwent alloSCT
Kewalramani et al. [32]	2006	24	48	PTCLu 58%; ALCL 17%; AITL 17%; Other 8%	aaIPI; 0/1   46%; 2/3   54%	Diverse	CR 63%; PR 37%	24% (5 y)	33% (5 y)	72
Kim et al. [33]	2007	40	44	PTCLu 50%; NK/T 25%; ALCL 13%; Other 13%	aaIPI; 0/1   45%; 2/3   53%; Unknown 3%	Diverse	CR 28%; PR 52%	No data	11.5 m (median)	16	29/40 transplanted 2.line
Smith et al. [34]	2007	32	44	ALCL 66%; PTCLu 34%	aaIPI (at Tx); 0/1   72%; 2/3   28%	BEC	No data	18% (5 y)	34% (5 y)	30	26/32 transplanted 2.line
Chen et al. [35]	2008	53	45	ALCL 34%; PTCLu 30%; AITL 17%; Other 19%	No data	Diverse	CR/PR 89%	25% (5 y); 9% (5 y)∗∗	48% (5 y); 37% (5 y)∗∗	60	38/53 transplanted 2.line
Lee et al. [36]	2008	47	42	NK/T 100%	aaIPI; 0/1   82%; 2/3   18%	CVB/BEAM/ MCEC (72%)	CR 58%	No data	No data	117	33/47 transplanted 2.line
Yang et al. [37]	2009	64	44	PTCLu 100%	aaIPI; 0/1   56%; 2/3   44%	BEAM/CVB (70%)	CR 33%; PR 58%	44% (3 y); 33% (3 y)∗∗	53% (3 y); 46% (3 y)∗∗	30	36/64 transplanted 2.line

Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group
∗classified according to the Working Formulation
∗∗for the subgroup of patients transplanted 2.line.